Cao, Z., An, L., Han, Y., Jiao, S
Because the triple-receptor design distinguishes it from earlier single- and dual-agonist peptides, the published literature has grown along an unusually legible arc: a founding discovery paper, a structural-biology study resolving how one peptide can occupy three distinct receptor complexes, and a sequence of clinical trials that broadened from glycemic endpoints into obesity and liver-fat endpoints
Well learn more about that when they actually publish the trial data
Meanwhile, we treated HepG2 cells with different concentrations of hDPP4 and found that the levels of IKK, p-P65 S536 /P65 ratio, and p-IKB S36 /IKB ratio were significantly enhanced to different degrees, but the activation of IKK-NFB signaling pathway induced by hDPP4 was remarkably inactivated by sitagliptin (Fig